ProCE Banner Activity

DESTINY-Breast06: T-DXd vs Chemotherapy by Pace of Progression on Previous ET in Patients With HR+/HER2-Low or HER2-Ultralow MBC

Conference Coverage
Slideset

Additional analyses from the phase III DESTINY-Breast06 trial demonstrate meaningful clinical benefit for median progression-free survival, response, and duration of response with T-DXd vs physician’s choice of chemotherapy across subgroups of patients with HR+/HER2-low or HER2-ultralow MBC defined by time to progression on first-line endocrine therapy plus CDK4/6 inhibitor, primary or secondary endocrine resistance, or disease burden.

Released: December 18, 2024

Expiration: June 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Lilly, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation